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Abstract 
Curcumin is a natural chemical compound found in Curcuma longa which has been 
used in several therapeutic applications such as an antitumor and anti-inflammation 
agent. However, curcumin has very limited water solubility and rapid in vivo 
degradation which limits its clinical application. To overcome these limitations, 
niosome nanoparticles were prepared by microfluidic mixing for curcumin 
encapsulation. Niosome nanoparticles are lipid-based, and composed of non-ionic 
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surfactants with cholesterol orientated into a membrane bilayer structure. Two different 
non-ionic surfactants were used and the mixing parameters were varied to optimise the 
characteristics of the prepared niosomes. The prepared niosomes had an average 
particle size ranging from 70-230 nm depending on the type of non-ionic surfactant 
used and the mixing parameter. Moreover, all the prepared niosomes were 
monodisperse with an average polydispersity index ranging from 0.07-0.3. All the 
prepared niosomes were spherical in shape as demonstrated by transmission electron 
microscopy. Curcumin was encapsulated with a maximum encapsulation efficiency 
around 60% using Tween 85 as the non-ionic surfactant. Niosomes prepared by 
microfluidic mixing provided controlled release of curcumin, as indicated by the release 
profile of curcumin overtime, thereby improving its therapeutic capability.  These 
results demonstrate that niosomes prepared by microfluidic mixing to encapsulate 
curcumin is a promising delivery system to reach target cells.  
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Introduction 
Curcumin is a natural product that is derived from the rhizome of the medicinal plant 
Curcuma longa Linn [1]. It has different therapeutic applications such as its use against 
inflammation and respiratory distress [2]. Moreover, in several studies, curcumin has 
been proven to have chemopreventive and chemotherapeutic effects against several 
types of cancer such as prostate and cervical cancers [3]. However, the therapeutic 
application of curcumin is limited by its high hydrophobicity with poor water solubility, 
photosensitivity, chemical instability, and rapid metabolism rate [4, 5]. Therefore, as a 
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result, systemic bioavailability is much reduced [6]. The use of nanoparticles as drug 
delivery systems is currently a corner stone in the field of drug delivery in order to 
improve the pharmacokinetics and pharmacodynamics of many drugs that have 
limitations in bioavailability [7]. 
Therefore, to improve the curcumin characteristics, nanoparticles have been proposed 
as carriers for curcumin to enhance its distribution and permeability [4]. Different types 
of nanoparticles have been investigated for curcumin delivery in order to prolong the 
plasma circulation time and enhance the localisation of the drug in the target tissues 
while reducing the unwanted side effects [8, 9]. Liposomes, solid lipid nanoparticles, 
dendrimers, micelles, polymeric nanoparticles, gold nanoparticles, and carbon 
nanotubes are among the most common types of nanoparticle delivery systems [10]. 
These efforts have been reported in several studies. For example, Guo et. al., were able 
to efficiently encapsulate curcumin into polymeric nanoparticles prepared using a 
fabricated microchannel. The prepared polymeric nanoparticles had an average particle 
size of 167 nm with a curcumin loading capacities of 15% [11]. Using niosome 
nanoparticles composed of different non-ionic surfactants prepared by the solvent 
evaporation method, Xu et. al., were able to achieve around 92% loading efficiency of 
curcumin which exhibited enhanced cytotoxic activity against ovarian cancer cells 
compared with freely dispersed curcumin [9]. Microfluidic mixing method for 
niosomes preparation is a recently developed method which allows for the control of 
the particles size and polydispersity during the process of formulation without the need 
for a size reduction step after the particles preparation [12]. This allows for the 
production of niosomes within the required characteristics in a single step which can be 
later used for large industrial scale preparations [13].  
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In the present work, niosomes were prepared by microfluidic mixing for curcumin 
encapsulation. Microfluidic mixing is a fast and reliable method for niosomes 
preparation which allow for the preparation of small and monodisperse particles within 
seconds. Different formulations encapsulating curcumin were prepared by microfluidic 
mixing by varying the surfactants and mixing parameters.  Previous work from our lab 
successfully developed empty niosomes through microfluidic mixing using different 
types of surfactants such as Tween 85 or Span 85 at different ratios. Therefore, in this 
work, these surfactants have been used to examine the efficiency of the prepared 
niosomes in curcumin encapsulation. The physicochemical characteristics were 
assessed and the ability of the niosomes to encapsulate and then release the loaded 
curcumin was evaluated.  
 
2. Materials and methods  
2.1. Materials  
Sorbitan monooleate (Span 80, SP80), Polyoxyethylenesorbitan trioleate (Tween 85, 
T85), Cholesterol (Chol), Curcumin, ethanol, methanol, cellulose membrane with 
molecular weight cut-off =14000, were purchased from Sigma–Aldrich (UK). 
 
2.2. Preparation of SP80 and T85 Niosomes by microfluidic mixing 
Niosomes, composed of SP80 or T85 as a surfactant with Chol, were prepared using 
microfluidic mixing on a NanoAssemblrTM (Benchtop, Precision NanoSystems Inc., 
Vancouver, Canada) as described previously [12]. The mixing process takes place in a 
microfluidic cartridge, with staggered herringbone structures, which have two inlets, 
one for the organic phase and the other for the aqueous phase. The organic phase was 
prepared by dissolving the lipid components (Sp80 or T85 with Chol at a 50:50 molar 
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ratio) with or without curcumin in ethanol while the aqueous phase was deionised 
water. The mixing process carried out at 50°C using a heating block. Both phases were 
injected into the microchannel using disposable syringes through syringe pumps. 
Niosomes were prepared at 1:1 and 3:1 flow rate ratios (FRR) between the aqueous and 
the lipid phases and all formulations were prepared at a total flow rate of 4 ml/min. The 
initial curcumin concentrations were 410 µg/ml and 210 µg/ml for formulations 
prepared at 1:1 and 3:1 FRR respectively. 
 
2.3. Removal of the un-encapsulated drug 
Un-encapsulated curcumin was removed by dialysis against 10X volume deionised 
water with continuous stirring at room temperature. At different time points, 1 ml was 
taken from the dialysis media and the amount of curcumin was measured using UV 
absorbance at 421nm using a HELIOS ALPHA ThermoSpectronic spectrophotometer 
(Thermo Fisher Scientific, UK). The curcumin concentration was determined against a 
calibration curve of the pure drug in methanol. After removal of each sample, 1 ml of 
deionised water was added to the dialysis media to maintain sink conditions. The 
dialysis was carried out until a constant curcumin concentration was detected in the 
dialysis media. 
2.4. Physicochemical characterisation of niosomes 
2.4.1. Particle size analysis  
The average particle size (ZAverage) and the PDI of the niosomes with and without the 
curcumin was measured by dynamic light scattering (DLS) using a Zetasizer Nano-ZS 
(Malvern Instruments Ltd., UK). All the samples were diluted at 1/20 using deionised 
water and the measurements in triplicate were taken at 25°C.  
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2.4.2. Niosome morphology  
The morphological examination of the prepared niosomes was determined using 
transmission electron microscope (TEM). Briefly, carbon-coated copper grids (400 mesh, 
agar scientific) were glow discharged in air for 30 seconds. Sample solution (3 ul) was drop-
cast on the grids and were then negatively stained using uranyl acetate. Each sample was 
allowed to dry afterwards in a dust-free environment prior to TEM imaging. The dried samples 
were then imaged using a JEOL JEM-1200EX TEM (JEOL, Tokyo, Japan) operating at an 
accelerating voltage of 80 kV. 
 
2.5. Determination of curcumin encapsulation efficiency  
Following removal of the un-encapsulated curcumin by dialysis, 100 µl of each 
niosome formulation (removed from the dialysis tubing) was lysed with methanol in 
order to release the encapsulated curcumin, which was then quantified at UV 
absorbance at 421nm. 
The encapsulation efficiency (EE) of curcumin was determined according to the 
following equation:  
EE% =  (Concentration of the encapsulated curcumin
/ initial curcumin concentration) ∗ 100%  
 
The experiments were performed in triplicate and the average ± SD reported.  
2.6. In vitro release profile of curcumin 
  
After removal of the un-encapsulated curcumin, 3 ml of each formulation loaded with 
curcumin were placed in separate dialysis tubes and dialysed against 10X volume of 
deionised water, at 37°C with continuous stirring. Samples were taken every day for a 
total of 21 days. 
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At each time point, 1 ml from the dialysis media from each niosomes formulation was 
taken and replaced with fresh 1 ml deionised water preheated at 37 °C. At each time 
point, the absorbance was measured at 421nm and the concentration of the released 
curcumin was determined against a calibration curve. The experiments were performed 
in triplicate and the average ± SD was reported.  
2.6. Statistical analysis 
Statistical significance was assessed by one-way analysis of variance (ANOVA) and 
Tukey multiple comparison test and t-test was performed for paired comparisons using 
Minitab® software, State College, PE. Differences were considered statistically 
significant for p values < 0.05. 
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3. Results and discussion 
3.1. Preparation of niosomes using microfluidic mixing 
Two types of surfactant (SP80 and T85) with chol were used to prepare niosomes. The 
aim was to see the effect of changing the surfactant type on the encapsulation of 
curcumin. Each formulation was prepared at two different FRR between the aqueous 
and the lipid phases during the microfluidic mixing. 
Table 1 shows the particle sizes calculated using DLS for the niosome formulations. At 
1:1 FRR, changing the surfactant type from SP80 to T85 resulted in a significant (p 
<0.05) increase in the average particle size and distribution for both empty and loaded 
particles. However, this was not the case at 3:1 FRR where the particle sizes and 
distributions were the same for both surfactant types. As can be seen from Table 1, the 
change in the FRR from 1:1 to 3:1 for the same noisome formulation resulted in a 
significant (p <0.05) decrease in particle size and distribution. For example, the size of 
the empty SP80 niosomes decreased significantly (p <0.05) from ~142 to ~70 nm by 
increasing the FRR from 1:1 to 3:1. These results confirm our previous studies 
describing niosome preparation by microfluidic mixing the same types of surfactants 
[12, 14]. 
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Table 1 Size and distribution for niosomes prepared by microfluidic mixing with two 
types of non-ionic surfactants at two different FRR. Results represent the mean ± SD of 
triplicate readings. 
Sample Size of empty 
particles (nm) 
PDI of empty 
particles 
Size of loaded 
particles (nm) 
PDI of 
loaded 
particles 
SP80 1:1 142.30 ± 1.05 0.14±0.05 144.50±1.84 0.17±0.05 
SP80 3:1 70.51 ± 0.43 0.11±0.04 70.26±0.20 0.09±0.02 
T85 1:1 228.33 ± 17.56 0.33±0.04 231.75±22.70 0.34±0.03 
T85 3:1 71.31±0.70 0.07±0.01 75.41±1.03 0.09±0.02 
 
 
3.2. Niosome morphology 
TEM was used to examine the morphological characteristics of the niosomes and the results 
are illustrated in figure 1. The results indicated that the prepared niosomes were almost 
spherical in shape with diameters matching the results obtained from the DLS. Moreover, the 
TEM images clearly confirm the effect of changing the FRR on the particle sizes, where smaller 
particles were obtained at 3:1 ratios compared to 1:1 ratios for both formulations. These results 
confirm previously reported results about niosomes prepared by microfluidic mixing [15]. 
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Figure 1 TEM images of (A) SP80 niosomes prepared at 1:1 FRR, (B) SP80 niosomes 
prepared at 3:1 FRR, (C) T85 niosomes prepared at 1:1 FRR, (D) T85 niosomes 
prepared at 3:1 FRR. 
 
3.3. Encapsulation of curcumin 
The potential of a nanoparticle delivery system can be predicted based on its encapsulation 
efficiency (EE) values. The EE data for the two niosome preparations, prepared using two 
different FRR was determined from a curcumin standard curve (Figure 2) as shown in Table 2. 
The use of T85 resulted in a significantly (p<0.05) higher encapsulation of curcumin compared 
to niosomes prepared using SP80 at the same FRR. Here at the same FRR, the only factor that 
was changed is the type of the non-ionic surfactant and this had a significant impact on the 
C D 
A B 
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final curcumin encapsulation. For example, niosomes prepared with SP80 at 3:1 FRR resulted 
in a curcumin EE of ~11%, while niosomes prepared using T85 at 3:1 FRR resulted in an EE 
of ~60%.  The increase in FRR from 1:1 to 3:1 resulted in a significant (p<0.05) increase in the 
EE values for both formulations. 
 
Figure 2. Curcumin standard curve measured by UV spectroscopy at 421nm. 
Table 2. Encapsulation efficiency (%EE) for curcumin using niosomes prepared with 
two different non-ionic surfactants at two different FRR. Results represent the mean ± 
SD of triplicate readings. 
Sample   Curcumin EE% 
SP80 1:1 1.21±0.03 
SP80 3:1 10.59±0.05 
T85 1:1 9.57±0.02 
T85 3:1 59.45±0.20 
 
Niosomes are composed of lipid bilayer structure encapsulating an aqueous compartment. 
Hydrophilic molecules are encapsulated in the aqueous compartment, while hydrophobic 
molecules are embedded in the membrane [16]. The EE of hydrophobic molecules is majorly 
affected by the lamellarity of the niosome membranes. Here, since the niosomes prepared by 
microfluidic are unilamellar, the main factor that seems to affect the EE of the niosomes is the 
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FRR and consequently the particle size since higher FRR resulted in a smaller particles and 
higher EE. This can be explained by the difference in the final chol concentrations when 
changing the FRR from 1:1 to 3:1. The increase in the FRR results in a lower concentration of 
chol and the non-ionic surfactant in the final niosome formulations. The presence of chol is a 
key factor that controls membrane rigidity; higher chol concentrations results in a less 
permeable and more rigid bilayer membrane. Moreover, the encapsulation of hydrophobic 
molecules is highly dependent on the bilayer membrane fluidity where higher encapsulations 
can be achieved with less rigid membranes [17]. In addition, higher chol concentrations might 
compete with the hydrophobic molecules and prevent its encapsulation during the self-
assemble of the lipid components into the bilayer structure [18]. Based on that, the increase in 
the FRR from 1:1 to 3:1 will result in a lower chol concentration in the final preparation, which 
means less rigid membranes and higher encapsulation for curcumin that is a hydrophobic 
molecules. This explains the observed EE results. 
Gupta et al., prepared niosomes composed of Span 60 and chol at a 70:30 molar ratio using the 
reverse evaporation method for nanoparticle preparation and achieved around 68% curcumin 
EE [19] which was comparable with our niosomes preparation using T85 at 3:1 FRR. Similarly, 
Manca et al., achieved curcumin EE of about 66% using liposomes containing polyanion 
sodium hyaluronate [8]. Ozeki et al., prepared a curcumin-loaded PEGylated PLGA through 
microfluidic mixing and achieved an EE of around 50% [20]. Here, high EE of around 60% 
was achieved using niosomes nanoparticles composed of T85 as a non-ionic surfactant. 
The encapsulation efficiency of the niosomes nanoparticles depends on several factors related 
to the characteristics of the non-ionic surfactant and the molar ratio between the surfactant and 
the cholesterol [21]. It has been reported that the size of the hydrophilic head group, the chain 
length of the non-ionic surfactant, the hydrophilic–lipophilic balance (HLB), and the phase 
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transition temperature (Tc) of the surfactant in the niosomes formulation would have 
significant effects on the encapsulation efficiency of different drugs [22]. Here in this study, 
two different types of non-ionic surfactants were used in the preparation of niosomes for 
curcumin encapsulation and since these two surfactants have different characteristics, this 
would explain the differences in the EE of curcumin between the prepared formulations.  
3.4. In vitro release profile of curcumin 
The in vitro release of curcumin from the niosomes is shown in Figure 3 and exhibited a 
biphasic pattern where an initial burst occurred followed by constant release and then another 
release pattern began followed by constant release for all the niosome preparations. The burst 
release rate reached a maximum within two days of storage and then the curcumin release 
concentration was constant until day 5 where an increase then followed. 
 
 
 
Figure 3 Curcumin release profile from the different niosome preparations when stored at 37°C. 
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These results suggest that the niosomes provide excellent release of curcumin from the carriers 
as indicated by figure 3. The release profile from all the formulations was almost identical 
despite having different EE. For example, the release profile of the T85 niosomes prepared at 
3:1 FRR, which had the highest EE of around 60%, was the same compared with the other 
niosomes formulations.  
All the prepared niosomes in this study had the same percentage of chol for membrane stability 
purposes [18], which is probably a contributing factor to the release profile being the same.  
Conclusions 
Here the preparation and characterization of niosomes nanoparticles prepared by microfluidic 
mixing for curcumin delivery was described. Both the type of the non-ionic surfactant and the 
mixing parameters in the microfluidic system remarkably affected the characteristics of the 
prepared niosomes.  
High curcumin encapsulation of around 60% can be achieved by preparing niosomes using T85 
and chol at 1:1 molar ratio. Microfluidic mixing allows the production of small and controlled 
size niosomes in a single step for the encapsulation of curcumin. These results will be useful 
for optimising the niosomes nanoparticles components to be used as a drug delivery system for 
curcumin and for other therapeutic agents.  
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